Cardinal Health Q3 revenue rises 11%, non-GAAP EPS up 35%, raises FY26 EPS guidance

Cardinal Health reported Q3 fiscal 2026 revenue of $60.9 billion, up 11% year-over-year, driven by growth in its Pharmaceutical and Specialty Solutions segment. GAAP operating earnings fell 30% to $509 million due to a $184 million goodwill impairment, but non-GAAP operating earnings rose 18% to $956 million, with non-GAAP diluted EPS increasing 35% to $3.17. The company raised its fiscal 2026 non-GAAP EPS guidance to $10.70-$10.80, reflecting improved segment performance and lower tax rates. Cardinal Health also reduced debt and completed $1 billion in share repurchases for FY26, signaling strong financial health and confidence in future growth.